JP2008505087A - インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 - Google Patents

インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 Download PDF

Info

Publication number
JP2008505087A
JP2008505087A JP2007519344A JP2007519344A JP2008505087A JP 2008505087 A JP2008505087 A JP 2008505087A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A JP2008505087 A JP 2008505087A
Authority
JP
Japan
Prior art keywords
glucagon
insulin
administered
hypoglycemia
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505087A5 (enExample
Inventor
ダニエル ティー． グリーン，
ロバート アール． ヘンリー，
Original Assignee
ディオベックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディオベックス， インコーポレイテッド filed Critical ディオベックス， インコーポレイテッド
Publication of JP2008505087A publication Critical patent/JP2008505087A/ja
Publication of JP2008505087A5 publication Critical patent/JP2008505087A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007519344A 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 Pending JP2008505087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (2)

Publication Number Publication Date
JP2008505087A true JP2008505087A (ja) 2008-02-21
JP2008505087A5 JP2008505087A5 (enExample) 2008-07-31

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519344A Pending JP2008505087A (ja) 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法

Country Status (11)

Country Link
EP (1) EP1778266A4 (enExample)
JP (1) JP2008505087A (enExample)
KR (1) KR20070029276A (enExample)
CN (1) CN101001638A (enExample)
AU (1) AU2005260025A1 (enExample)
CA (1) CA2571030A1 (enExample)
IL (1) IL180361A0 (enExample)
MX (1) MXPA06014970A (enExample)
NO (1) NO20070174L (enExample)
WO (1) WO2006004696A2 (enExample)
ZA (1) ZA200700708B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533129A (ja) * 2020-06-26 2023-08-02 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059764A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
EP3344231B1 (en) * 2015-09-04 2022-04-13 Latitude Pharmaceuticals, Inc. Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
US11357829B2 (en) 2017-02-03 2022-06-14 Vanderbilt University Systems, compositions and methods for treating diabetes
BR112020000447A2 (pt) * 2017-07-14 2020-07-21 Xeris Pharmaceuticals, Inc. métodos de tratamento de hiperinsulinismo congênito
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
JP2006508975A (ja) * 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533129A (ja) * 2020-06-26 2023-08-02 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法
JP7828300B2 (ja) 2020-06-26 2026-03-11 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法

Also Published As

Publication number Publication date
NO20070174L (no) 2007-03-13
ZA200700708B (en) 2009-03-25
AU2005260025A1 (en) 2006-01-12
IL180361A0 (en) 2007-06-03
EP1778266A4 (en) 2009-09-09
WO2006004696A2 (en) 2006-01-12
CA2571030A1 (en) 2006-01-12
EP1778266A2 (en) 2007-05-02
MXPA06014970A (es) 2007-03-07
CN101001638A (zh) 2007-07-18
WO2006004696A3 (en) 2006-10-26
KR20070029276A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
US7655618B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US12303554B2 (en) Use of ultrarapid acting insulin
JP2006514990A5 (enExample)
WO2015148905A1 (en) Use of ultrarapid acting insulin
KR20070029276A (ko) 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
HK1108567A (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
ZA200504944B (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120425